Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hutchison Chi-Med to File for Approval of Two Cancer Drugs in 2016

publication date: Mar 2, 2015
Hutchison Chi-Med plans to file two New Drug applications for innovative cancer drugs in 2016, said Christian Hogg, CEO of the company, in an upbeat year-end earnings report. The company expects results from a Phase II trial of fruquintinib as a treatment for colorectal cancer soon, which will trigger a milestone payment from Lilly. It also expects milestones from savolitinib, a treatment for kidney and gastric cancer that is out-licensed to AstraZeneca later in 2015. Chi-Med will file for China approval of fruquintinib and US approval of savolitinib. More details....

Stock Symbols: (AIM: HCM) (NYSE: LLY) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital